Sanofi MS drug tolebrutinib misses goal in relapsing disease trials By Reuters Stocks September 2, 2024 By Ludwig Burger (Reuters) – Sanofi (NASDAQ:)’s most advanced multiple sclerosis (MS) drug candidate has missed the main goal of…